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p63 deficiency activates a program
of cellular senescence and leads
to accelerated aging
William M. Keyes,1 Ying Wu,1 Hannes Vogel,2 Xuecui Guo,1 Scott W. Lowe,1 and Alea A. Mills1,3
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; 2Stanford University,
Stanford, California 94305, USA
The p53 tumor suppressor plays a key role in organismal aging. A cellular mechanism postulated to drive the
aging process is cellular senescence, mediated in part by p53. Although senescent cells accumulate in elderly
individuals, most studies have relied on correlating in vitro senescence assays with in vivo phenotypes of
aging. Here, using two different mouse models in which the p53-related protein p63 is compromised, we
demonstrate that cellular senescence and organismal aging are intimately linked and that these processes are
mediated by p63 loss. We found that p63+/− mice have a shortened life span and display features of accelerated
aging. Both germline and somatically induced p63 deficiency activates widespread cellular senescence with
enhanced expression of senescent markers SA--gal, PML, and p16INK4a. Using an inducible tissue-specific p63
conditional model, we further show that p63 deficiency induces cellular senescence and causes accelerated
aging phenotypes in the adult. Our results thus suggest a causative link between cellular senescence and aging
in vivo, and demonstrate that p63 deficiency accelerates this process.
[Keywords: Aging; mouse models; p63; senescence]
Supplemental material is available at http://www.genesdev.org.
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Multicellular organisms with renewable tissues have
evolved several mechanisms for regulating aberrantly
growing cells, most notably apoptosis and senescence
(Campisi 2001). Cellular senescence is a form of irrevers-
ible growth arrest, originally described for end-stage pro-
liferative cells in culture (Hayflick 1965), but now
known to be induced by multiple stimuli including
DNA damage, oxidative stress, chemotherapy, and ex-
cess mitogenic stimuli such as oncogene activation (Ser-
rano et al. 1997; Campisi 2001; Schmitt et al. 2002). Se-
nescence is controlled by the p53 and Rb tumor suppres-
sors, resulting in accumulation of key senescence
proteins such as the tumor suppressors p16INK4a, p19Arf,
and promyelocytic leukemia protein (PML) (Serrano et
al. 1997; Ferbeyre et al. 2000; Pearson et al. 2000; Narita
et al. 2003; de Stanchina et al. 2004). PML protein is a
component of nuclear structures known as nuclear bod-
ies (NBs) that are involved in processes such as senes-
cence, apoptosis, and differentiation (Salomoni and Pan-
dolfi 2002). However, in response to senescence-induc-
ing stimuli, the size and number of PML NBs have been
shown to increase in cultured cells (Ferbeyre et al. 2000;
Pearson et al. 2000). Although mostly studied in vitro,
cellular senescence has been correlatively linked to the
aging process at the level of the whole animal, thus im-
plicating many of the factors that regulate senescence as
contributing to organismal aging (Sharpless and DePinho
2004; Campisi 2005).
In contrast to p53’s established role in mediating tu-
mor-suppressive mechanisms such as senescence, the
p53-related protein p63 has until now been attributed
mainly a developmental role due to its ability to regulate
proliferation, differentiation, and cell fate (Mills et al.
1999; Yang et al. 1999; Koster et al. 2004; Kurita et al.
2004). p63-deficient mice exhibit striking epithelial de-
fects, including complete absence of skin, hair, and
many ectodermal derivatives (Mills et al. 1999; Yang et
al. 1999). Whereas these loss-of-function studies clearly
demonstrated that p63 is necessary for stratified epithe-
lia to form, gain-of-function studies revealed that p63 is
sufficient for dictating epithelial cell fate (Koster et al.
2004). However, in addition to its role in formation of
the skin during development, p63 also functions to re-
plenish epithelia of mature skin (Koster et al. 2004)—a
cell type that is continually replaced about once every 2
wk in humans. Some reports indicate that p63 is essen-
tial for maintaining the stem cell pool, while others sug-
gest it is needed for cell fate decisions (McKeon 2004).
Together, these studies highlight the fact that p63 pos-
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sesses roles in differentiation and rejuvenation of epithe-
lia, both during embryonic development and in mature
epithelia.
The p63 gene is transcribed from dual promoters, and
undergoes alternative splicing to generate multiple tran-
scripts that encode different p63 proteins (Yang et al.
1998). These p63 isoforms can be classified into two ma-
jor subtypes: those that possess an N-terminal transac-
tivation domain similar to that of p53 and those that
lack this domain, referred to as the transactivating (TA)
and the dominant-negative (DN) isoforms, respectively.
The DN isoforms are the most abundant isoform class in
mature proliferating epithelia such as the skin, and ex-
pression of these isoforms is dramatically down-regu-
lated during differentiation and growth arrest (Yang et al.
1998; Westfall et al. 2003; Koster et al. 2004). In addition
to differences between different p63 isoforms at the N
termini, alternative splicing generates , , and  iso-
forms for both the TA- and DN-isoform classes, produc-
ing six different p63 proteins that could potentially in-
teract with distinct p63 isoforms and/or additional mem-
bers of the p53 protein family to generate a myriad of
complexes with diverse transcriptional abilities.
Although p63-deficient mouse models generated by us
and by others have been extremely informative for un-
covering the physiological role of p63 during develop-
ment, the perinatal lethality of p63−/− mice prevents as-
sessment of p63 function past the neonatal stage (Mills
et al. 1999; Yang et al. 1999). Here, we describe a novel
p63 conditional mouse model that inactivates all p63
isoforms in an inducible and tissue-specific manner, pro-
viding a system for assessing the biological role of p63 in
the adult. Using both the p63−/− and the p63 conditional
mouse models, we describe two novel roles for p63 in
regulating senescence and aging through modulation of
p16INK4a and PML, providing in vivo evidence linking
these two processes.
Results
During the course of an extensive study, we noticed that
although p63+/− mice were not susceptible to spontane-
ous tumors (W.M. Keyes and A.A. Mills, unpubl.), they
had a significant reduction in life span (Fig. 1A). Whereas
the median life span for wild-type mice (n = 74) was 121
wk, that of p63+/− mice (n = 104) was only 95 wk. This
decrease in life span was highly significant (P < 0.0001,
log-rank test), and represented a 21.5% decrease in lon-
gevity. Intriguingly, the decreased longevity of p63+/−
mice was almost identical to that observed for p53+/m
mice, a mouse model in which enhanced p53 activity
provided resistance to spontaneous tumors while simul-
taneously accelerating the aging process (Tyner et al.
2002). Some of the p63+/− cohort died with no signs of
malignancy, and others developed life-threatening le-
sions or appeared sickly, and several features character-
istic of age-related decline were noted (Fig. 1B–G; Supple-
mentary Table 1). Of the 104 p63+/− mice subjected to
detailed histology, 8% (n = 8) were found dead with no
macroscopic or microscopic signs of malignancy. A large
percentage of this cohort had to be euthanized for one or
more of the following reasons: 52% (n = 54) had severe
skin lesions or infections, 35% (n = 36) were extremely
weak, 19% (n = 20) had palpable lymph nodes, 14%
(n = 14) had an enlarged abdomen, 12% (n = 12) had vis-
ible signs of hemorrhage, 6% (n = 6) had rectal prolapse,
and 2% (n = 2) had an aberrant circling behavior.
Hyperplastic epithelia were common, and skin lesions
that often progressed in severity were frequently ob-
served. Histological analysis of biopsies from ulcerated
skin showed severe abscesses in the dermis, which often
contained bacterial inclusions (Fig. 1B). Many of the
p63+/− mice showed evidence of chronic infection of the
skin, subcutaneous tissues, oropharynx, and genitouri-
nary tract.
Since p63 is expressed at high levels in proliferating
Figure 1. Life span is decreased in p63+/− mice. (A) Over the
course of a >2.2-yr study, the median life span for wild-type
mice (n = 74) was 121 wk, whereas that of p63+/− mice (n = 104)
was 95 wk, a difference of 21.5% (P < 0.0001, log-rank test).
p63+/− mice frequently developed hyperplastic lesions in a vari-
ety of epithelia. (B–G) Histological analysis of tissues of p63+/−
mice. (B) Dorsal back skin. (C) Dorsal surface of the tongue. (D)
Rectum. (E) Vagina. (F) Cornea of the eye. (G) Glomerulus of the
kidney.
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cells of stratified epithelia other than that of the skin, we
extended our analysis to other epithelial tissues. Indeed,
in addition to the defects evident in the epidermis, se-
vere lesions of other epithelia such as that of the tongue,
rectum, cervix, and cornea of the eye were observed (Fig.
C–F). These defects included acanthosis of epithelia of
the tongue, rectal prolapse, vaginal cervicitis, and cor-
neal granulation of the surface of the eye. We were not
surprised to find the most severe pathology in p63-ex-
pressing tissues. In addition to these defects, we also
noticed additional phenotypes in tissues of nonsqua-
mous epithelia. Several mice had chronic nephritis of the
kidney—an organ in which p63 is expressed (Fig. 1G;
A.A. Mills, unpubl.). Of note was the observation that
the kidney pathology observed in p63+/− mice resembles
that of the human kidney from patients of advanced age
(Rodwell et al. 2004).
Since longevity and fitness were significantly compro-
mised in mice carrying a single disrupted p63 allele that
inactivates all p63 isoforms and reduces p63 to haploid
levels, we next developed a system that allowed us to
study the consequence of somatic p63 loss by generating
a p63 conditional model that provided inducible, tissue-
specific p63 disruption (Fig. 2A). This approach bypasses
the neonatal lethality caused by germline p63 deficiency
(Mills et al. 1999; Yang et al. 1999), hence allowing us to
investigate the consequence of p63 deficiency in the
adult. We had previously used embryonic stem cell tech-
nology to generate the p63flox mouse model, which har-
bors a p63 allele with a pair of loxP sites encompassing
exons encoding the DNA-binding domain (DBD) (Mills
et al. 2002). This region is highly homologous to the
DBD of p53, is essential for p63’s transcriptional activ-
ity, and is shared by all p63 isoforms (Yang et al. 1998).
Mice homozygous for the p63flox allele were viable, fer-
tile, and did not display any detectable phenotype (Mills
et al. 2002). As expected, expression of Cre resulted in
removal of exons encoding the majority of the DBD, con-
verting the p63flox allele to the p63Brdm3-null allele. In
contrast to the wild-type phenotype of p63flox/flox ani-
mals, p63Brdm3/Brdm3 embryos were phenotypically simi-
lar to the p63−/− embryos that we characterized previ-
ously (Mills et al. 1999, 2002).
To establish a system for disrupting p63 in vivo, we
crossed the p63flox strain to the K5CrePR1 mouse strain
(Fig. 2A), which harbors a transgene that uses the keratin
5 (K5) promoter to express mifepristone-inducible Cre
within proliferating keratinocytes of stratified epithelia
such as the skin in a pattern that overlaps that of endog-
enous p63 (Mills et al. 1999; Yang et al. 1999; Zhou et al.
2002). Crosses between mice with the appropriate p63flox
and K5CrePR1 alleles produced a subset of progeny that
were homozygous for the p63flox allele that also had the
inducible Cre transgene (Fig. 2B, lane 6). In some cases,
p63Brdm2 mice that carry a null p63 allele (Mills et al.
1999) were included in the mating scheme so that
p63flox/Brdm2; K5CrePR1 progeny were generated (Fig.
2B, lane 5). p63flox/flox; K5CrePR1 and p63flox/Brdm2;
K5CrePR1 progeny (referred to as “p63 ablated” after
Cre-mediated p63 disruption) and sibling controls of a
variety of genotypes that would not facilitate p63 nulli-
zygosity (referred to as “controls”; e.g., Fig. 2B, lanes 1–4)
were generated, and Cre was activated in utero or after
birth by treatment with mifepristone. Cre-mediated ex-
cision of exons encoding the DBD occurred in p63-
ablated progeny, but not in sibling controls that were
also exposed to inducer (data not shown). Importantly,
this system inactivates all six p63 isoforms that have
been described since DBD-encoding exons excised by
Cre are common to all p63 proteins (Yang et al. 1999;
Mills et al. 2002). Indeed, Western analyses revealed that
DNp63, the predominant p63 isoform expressed in ma-
ture skin, is efficiently ablated in response to mifepris-
tone treatment in p63-ablated, but not in control skin
(Fig. 2C). Similarly, immunofluorescent analyses dem-
onstrated that the number of p63-positive cells was dra-
matically reduced in response to Cre activation in p63-
ablated skin, relative to that of controls (Fig. 2D). These
analyses demonstrate that the p63 conditional model
provides efficient disruption of the p63 locus, hence in-
activating p63 in vivo.
To evaluate whether the p63 conditional model could
be used to generate progeny that phenocopied p63-defi-
cient embryos generated by germline p63 deficiency, we
next activated Cre in utero by administration of mife-
pristone during midgestation. Microscopic examination
of control, p63−/−, and p63-ablated progeny at the whole-
mount level revealed that p63 ablation induced in utero
caused a phenotype that was similar to that of p63−/−
mice (Fig. 3A). Indeed, somatic p63 ablation in stratified
epithelia caused dramatic developmental defects of the
limbs, skin, and facial region that are characteristic of
germline p63 deficiency (Mills et al. 1999; Yang et al.
1999). Histological analysis of the skin of p63-ablated
embryos demonstrated that whereas the epidermis was
stratified in control skin, it was devoid of stratified struc-
ture in p63-ablated skin (Fig. 3B). To evaluate the extent
of defects in epidermal morphogenesis imposed by p63
deficiency, we used immunofluorescence to examine the
expression pattern of markers of distinct stages of epi-
dermal differentiation in control and p63-ablated skin
(Fig. 3B). Although the proliferating keratinocyte marker
keratin 14 (K14) was expressed robustly in control skin,
it was not detectable in p63-ablated tissue, indicating
that p63 deficiency correlated with a lack of proliferating
epidermal cells. Similarly, early-stage epidermal markers
keratins 1 and 10 (K1/10), as well as the late-stage epi-
dermal marker fillaggrin, were expressed in control skin,
but as in p63−/− skin (Mills et al. 1999), these markers
were not detectable in p63-ablated skin (Fig. 3B). Thus,
these analyses demonstrate that ablation of p63 can gen-
erate embryos that have a similar phenotype to that of
p63−/− embryos in which the program of epidermal mor-
phogenesis has been arrested.
Given the decrease in life span and compromised fit-
ness of mice with haploid levels of p63, combined with
the finding that morphogenesis is arrested in p63-defi-
cient embryos, we asked whether cellular senescence
caused by compromised p63 function might be an under-
lying cellular mechanism for age-related decline at the
Keyes et al.
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Figure 2. Inducible, tissue-specific Cre-mediated p63 disruption in vivo. (A) Schematic diagram of the K5CrePR1 and p63flox alleles
used to generate the p63 conditional system. The K5CrePR1 transgene uses the K5 promoter to drive expression of the Cre-proges-
terone receptor fusion protein, which provides expression of an inducible form of Cre specifically within stratified epithelia such as
the skin. The p63flox allele contains a pair of loxP sites (yellow triangles) encompassing the majority of the DBD (red). Excision of
DBD-encoding exons by Cre disrupts p63, alters the reading frame of any potential p63 transcript, and inactivates all p63 isoforms.
p63flox and p63Brdm3 (disrupted) alleles were identified by amplifying the unique junctions using the PCR primers shown (arrows). (B,
top) Southern blot hybridization of DNA samples from E17.5 embryos showing endogenous (p63), null (p63Brdm2), and floxed (p63flox)
p63 alleles. (Bottom) PCR was used to amplify -actin as a positive control and the K5CrePR1 transgene from the same templates
analyzed above. p63flox/Brdm2; K5CrePR1 (lane 5) and p63flox/flox; K5CrePR1 (lane 6) have the correct genotype to facilitate Cre-mediated
p63 disruption in response to mifepristone treatment. (C) Western blot analyses of lysates prepared from dorsal back skin biopsies
obtained from E17.5 wild-type and p63−/− embryos, as well as from embryos that had been treated with mifepristone at E10.5. DNp63,
the predominant p63 isoform in mature epidermis, is efficiently ablated in utero. (D) p63 immunofluorescence and quantitation of
p63-expressing cells from post-natal day 4 (P4) dorsal back skin from control (p63Brdm2/flox) and p63-ablated (p63flox/Brdm2; K5CrePR1)
mice after treatment with inducer at P2. Quantitation of proliferating cells was evaluated by counting the number of fluorescently
labeled cells per total number of cells in both the interfollicular and follicular epidermis. Bar, 100 µM.
Compromised p63 in senescence and aging
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organismal level. To investigate whether p63 deficiency
enhanced senescence in vivo, we examined the degree of
senescence in response to both germline and somatic p63
deficiency by assaying for endogenous senescence-asso-
ciated -galactosidase (SA--gal) activity, an established
marker of cellular senescence (Dimri et al. 1995). When
SA--gal activity was assessed at the whole-mount level,
we found that control late-stage embryos had very low
levels of endogenous SA--gal activity, whereas both
p63−/− and p63-ablated embryos expressed high levels of
this senescence marker (Fig. 4A). Histological analysis of
skin sections from these SA--gal assayed embryos re-
vealed that both p63−/− and p63-ablated skin have an
increase in the number of senescent cells relative to that
of control tissue (Fig. 4A). To ensure that the intense
staining for SA--gal activity was not simply an artifact
of the whole-mount procedure, we next analyzed for SA-
-gal activity in skin biopsies by first preparing frozen
sections of the skin, and subsequently performing the
SA--gal assay in situ (Fig. 4B). Consistent with the re-
sults obtained using the whole-mount procedure, skin
from control embryos was stratified and essentially de-
void of endogenous SA--gal activity. In contrast, wide-
spread senescence was detected throughout the undevel-
oped surface of p63−/− skin, with an intense focal distri-
bution of SA--gal-positive cells in p63-ablated skin. The
different patterns of senescence observed in p63−/− and
p63-ablated skin likely reflects the differentiation stage
at which p63 deficiency occurred in the two systems.
Epithelia of p63−/− embryos do not express p63, and
therefore morphogenesis of stratified epithelia does not
progress past the undifferentiated ectodermal stage. In
contrast, p63 is initially expressed normally in the single
layered ectoderm of p63flox/flox; K5CrePR1 embryos.
TAp63 isoforms are the predominant isoforms expressed
in the undifferentiated ectoderm, and these p63 proteins
are detectable at embryonic day 7.5 (E7.5) and mediate
initiation of the stratification program (Koster et al.
2004). When Cre is induced at E8.5, the ectoderm has
already begun to differentiate, but has not yet stratified.
Therefore, p63 deficiency that is induced after epithelial
morphogenesis has initiated causes a different pattern of
Figure 3. Cre-mediated p63 disruption induced
by mifepristone treatment efficiently ablates p63
in utero. (A) Whole-mount microscopy of con-
trol, p63−/−, and p63-ablated embryos at E17.5
demonstrates that p63-ablated mice have a phe-
notype similar to that of p63−/− embryos. Note
that the p63-ablated embryo shown was gener-
ated by administration of mifepristone at E8.5,
and the embryo was allowed to develop until har-
vest at E17.5. (B) Skin biopsies from control and
p63-ablated embryos similar to those shown in A
were examined by histological and immunofluo-
rescent analyses. Epidermal morphogenesis was
halted in response to Cre-mediated p63 ablation
induced by mifepristone treatment at E8.5, as
seen by the lack of stratification by histological
analysis (H&E) and by the absence of expression
of proliferating (K14), early-stage (K1/K10), and
late-stage (fillaggrin) epidermal markers by im-
munofluorescence in p63-ablated skin. Bar,
10 µM.
Keyes et al.
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cellular senescence than does germline p63 deficiency in
which the ectoderm never commits to the stratified lin-
eage. Thus, senescence occurs in response to both germ-
line and somatically induced p63 deficiency in vivo.
To evaluate whether senescence induced by p63 defi-
ciency in the embryo could also be observed at the cel-
lular level, we investigated the consequence of p63 ab-
lation in primary keratinocytes, a cell type in which p63
is expressed robustly. Primary keratinocyte cultures
were first established from p63flox/flox neonates, and p63
was disrupted by infecting the cultures with retroviral
Cre (Fig. 4C). Parallel cultures were either uninfected or
infected with green fluorescent protein (GFP)-expressing
retrovirus. To assay these keratinocytes for Cre-medi-
ated excision of exons encoding the DBD, we prepared
genomic DNA and performed PCR using primers spe-
cific for the p63Brdm3 allele (see Fig. 2A). Excision of
DBD-encoding exons was undetectable in control cul-
tures but was efficient in Cre-infected cultures (Fig. 4C).
To correlate p63 disruption with the extent of cellular
senescence, keratinocytes were assayed for endogenous
SA--gal activity, and the percentage of SA--gal positive
cells per total number of cells in each culture was as-
sessed (Fig. 4C). Senescence was induced in Cre-infected
cultures but not in control cultures: p63-ablated cells
ceased proliferating, became flattened and enlarged, and
expressed high levels of endogenous SA--gal (Fig. 4C).
The number of senescent cells in uninfected versus p63-
ablated cells represented an ∼10-fold increase. In con-
trast, parallel experiments in which wild-type primary
keratinocyte cultures that had been infected with retro-
viral Cre were subjected to the SA--gal assay did not
have an appreciable increase in the percentage of senes-
cent cells over background levels (data not shown), dem-
onstrating that senescence is due to p63 loss as opposed
to being an effect of Cre toxicity (Loonstra et al. 2001),
consistent with the lack of senescence in control em-
bryos that carried the K5CrePR1 transgene but lacked
Figure 4. The senescence marker SA--
gal is induced in response to both germline
and somatically induced p63 deficiency in
vivo, and in primary keratinocytes in cul-
ture. (A) A whole-mount assay for endog-
enous SA--gal activity was performed on
E17.5 p63+/+, p63−/−, and p63-ablated em-
bryos; skin sections from SA--gal assayed
embryos were subjected to histological
analysis; the intense blue color observed
in p63−/− embryos is indicative of senes-
cent cells. Bar, 100 µM. (B) Dorsal back
skin biopsies from E17.5 control, p63−/−,
and p63-ablated embryos (treated with
mifepristone at E8.5) were stained with
Dapi to show histology (bottom panels)
and assayed for endogenous SA--gal ac-
tivity (top panels). Positive (blue) cells
were essentially undetectable in control
skin, whereas p63−/− and p63-ablated skin
had a dramatic increase in cellular senes-
cence. Bar, 100 µM. (C) Primary keratino-
cyte cultures from p63flox/flox mice were
uninfected, or infected with GFP-express-
ing (GFP) or Cre-expressing (Cre) retrovi-
rus. DNA prepared from these cultures
was subjected to PCR to identify the dis-
rupted p63Brdm3 allele. -Actin was used
as a positive control. Cultures were sub-
jected to the SA--gal assay, and senescent
cells were quantitated. Bar, 100 µm.
Compromised p63 in senescence and aging
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the p63 alleles required for complete p63 ablation (data
not shown). Together, these results demonstrate that as
in p63-deficient skin in vivo, p63 deficiency induces cel-
lular senescence in primary keratinocytes in vitro, con-
sistent with the idea that cellular senescence is a cell-
autonomous effect in this setting.
Senescent cells have withdrawn from the cell cycle,
and therefore induction of cellular senescence correlates
with decreased proliferative potential. To examine pro-
liferation in control and p63-deficient skin, timed mat-
ings between p63+/− mice were performed, and embryos
were subjected to an in utero bromodeoxyuridine pulse
to label proliferating cells (Fig. 5A). Embryos were har-
vested, skin sections were prepared, and cells that had
incorporated BrdU at the time of the pulse (i.e., cells in
S-phase) were identified by immunofluorescence. Quan-
titation of proliferating cells revealed that p63 deficiency
caused a significant (approximately threefold; P < 0.001)
reduction in the number of proliferating cells in vivo, a
finding consistent with the observation that p63 defi-
ciency causes cellular senescence.
Key mediators and inducers of senescence in vitro are
p53, p16INK4a, and PML (Ferbeyre et al. 2000; Pearson et
al. 2000; Narita et al. 2003). To assess whether p63 de-
ficiency evokes similar pathways, we evaluated the pat-
tern of expression of these senescence mediators by im-
munofluorescence (Fig. 5B). Whereas control skin had a
restricted pattern of PML expression, there was in-
creased expression of PML in both p63−/− and p63-ab-
lated skin. Importantly, given PML’s role in senescence,
immunofluorescence revealed that both the size and
number of PML bodies were increased in p63-deficient
skin, and multiple PML isoforms were induced by p63
deficiency, with somatic p63 deficiency appearing to
have an enhanced effect (Fig. 5B,C). When we evaluated
PML expression at the transcript level, we did not detect
an increase in PML expression in p63-deficient skin, sug-
gesting that PML levels are being modified post-tran-
scriptionally (Fig. 5C). p16INK4a was undetectable in con-
trol skin, but was increased in a pattern similar to that
observed for endogenous SA--gal activity in both p63−/−
and p63-ablated skin (cf. Figs. 4A,B and 5B). We found
that not all p63-compromised embryos expressed equiva-
lent levels of p16INK4a at the protein (Fig. 5B) or tran-
Figure 5. Key mediators of cellular senes-
cence are induced in response to p63 defi-
ciency in utero. (A) In vivo proliferation
was assessed in E17.5 embryos using the
BrdU incorporation assay. After an in
utero pulse with BrdU, embryos were har-
vested and dorsal back skin biopsies from
p63+/+ (Control) and p63−/− embryos were
subjected to immunofluorescent analysis
to detect cells that incorporated BrdU.
(Right) Proliferating cells were quanti-
tated, showing that p63 deficiency causes
decreased proliferation in vivo (±SEM;
P < 0.001). Bar, 10 µm. (B) Immunofluores-
cence for PML and p16INK4a in p63+/+,
p63−/−, and p63-ablated embryonic skin at
E17.5. Bars represent 10 µm for p16INK4a
and 50 µm for PML. (C) Western blot
analysis for PML in representative p63+/+
(wt), p63−/− (−/−), and p63-ablated (ab) skin
lysates. Real-time PCR analysis was used
to determine PML and p16INK4a expression
at the transcript level.
Keyes et al.
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script level (Fig. 5C), suggesting that up-regulation of
p16INK4a in response to p63 deficiency is a transient
event that peaks at a specific developmental time point.
In contrast to the increased expression of PML and
p16INK4a, we were unable to detect any change in p53
expression in p63-compromised skin (data not shown),
even though enhanced p53 expression has been shown to
correlate with cellular senescence in some experimental
settings (Campisi 2001). To evaluate whether senescence
induced by p63 deficiency required p53, we intercrossed
mice carrying inactivated p63 and p53 alleles and as-
sayed p63−/−; p53−/− embryos for SA--gal activity
(Supplementary Fig. 1). Using the whole-mount assay de-
scribed above, we found that p63−/−; p53−/− embryos ex-
pressed SA--gal in a pattern similar to p63−/− embryos,
indicating that senescence induced in response to germ-
line p63 deficiency is p53-independent in vivo. Thus, we
demonstrate that senescence induced by p63 deficiency
causes enhanced expression of several key senescence
mediators in embryonic skin in vivo.
Cellular senescence has been correlatively linked as a
causative factor in organismal aging. To investigate
whether the effect of p63 ablation on senescence ob-
served in the embryo and in cultured cells would also
lead to senescence in the adult, we used the p63 condi-
tional system to examine the effect of p63 ablation in
adult skin in vivo. Mice with the appropriate combina-
tion of alleles to facilitate Cre-mediated recombination
were generated as described above. p63-ablated and age-
and sex-matched sibling controls were treated with mife-
pristone at 8 mo of age (Fig. 6). Whereas control mice
carrying the K5CrePR1 transgene did not develop any
detectable phenotype in response to Cre activation even
though Cre toxicity has been noted in some experimen-
tal settings (Loonstra et al. 2001), p63-ablated mice dis-
played striking age-associated phenotypes (Fig. 6A;
Supplementary Table 1). Some aging features such as alo-
pecia can first be noticed around 1 mo of age even prior
to induction, suggesting that expression of Cre can occur
in the absence of inducer, and these phenotypes progress
in severity over time. p63 deficiency in the adult caused
severe alopecia, defects of the skin, and pronounced lor-
dokyphosis, an age-related curvature of the spine that
becomes more severe in p63-ablated mice as they age
Figure 6. Aging features and senescence-
associated markers are induced in re-
sponse to p63 deficiency in adult mice. (A)
Cre-mediated ablation of p63 in vivo in
control (top panel) and ablated (bottom
panel) adult mice at 8 mo of age. Note the
pronounced lordokyphosis and alopecia
caused by p63 deficiency. (B) Weight of
age- and sex-matched sibling pairs of con-
trol and p63-ablated adult mice at 7, 20,
and 22 mo of age, expressed as a percent-
age of control. (C) The tissue specificity of
Cre-mediated p63 disruption in adult con-
trol (c), ablated (a) mice was evaluated by
PCR amplification of the p63flox and
p63Brdm3 alleles from genomic DNA ob-
tained from different tissues. (Sk) Skin;
(To) tongue; (Fs) forestomach; (Th) thy-
mus; (Mu) muscle; (Lu) lung; (Li) liver; (Ki)
kidney; (Re) reproductive tract (female);
(Bf) brown fat; (Sp) spleen; (He) heart; (Br)
brain; (m) BstEII-digested  DNA; (−) nega-
tive water control; (+) genomic DNA from
a p63Brdm3/+ mouse. (D–G) Dorsal back
skin sections of control and p63-ablated
8-mo-old mice, showing the pronounced
aging-associated features in the skin of
p63-ablated mice. (D) Hematoxylin and
eosin staining. (E) K14 (green) and K1/K10
(red). (F) p63 (green) and K1/K10 (red). (G)
SA--gal activity. (H) p16INK4a expression.
Bars: D,E,G,H, 100 µm; F, 10 µm.
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(Fig. 6A). In addition to the age-related features evident
in the skin and its associated structures, p63-ablated
mice had substantial weight loss as compared with age-
and sex-matched sibling controls (Fig. 6B).
To investigate whether Cre-mediated p63 disruption
was limited to specific tissues or was occurring glob-
ally, multiple tissues were harvested from 20-mo-old fe-
male control (p63flox/+) and p63-ablated (p63Brdm2/flox;
K5CrePR1) siblings that had been induced at 9 mo of age.
Genomic DNA was harvested from a panel of 13 tissues,
and a PCR assay was performed that could differentiate
between p63flox (“wild type”) and p63Brdm3 (disrupted)
alleles (Fig. 6C; see also Fig. 2A). Whereas the p63flox
allele was detected in all tissues, the disrupted p63Brdm3
allele was detected in a tissue-specific manner. Cre-me-
diated excision of the DBD-encoding exons was readily
detectable in tissues from ablated mice that express K5
such as skin, tongue, forestomach, and thymus, in agree-
ment with the ability of the K5 promoter to drive Cre
expression in these tissues. In contrast, p63 disruption
was not detected in other tissues such as brain and heart
that do not express endogenous K5. Other tissues in
which Cre-mediated p63 disruption was detected were
muscle and lung. Although this was initially unex-
pected, a previous study reporting a lung phenotype in a
transgenic mouse model that used the K5 promoter to
drive transgene expression (Carraresi et al. 2001) and the
report that K5 colocalizes with the muscle-specific pro-
tein desmin (Hirako et al. 2003) make it likely that these
tissues express endogenous K5 and therefore that this
promoter is activating Cre and disrupting p63 in these
tissues. The PCR amplification product specific for
p63Brdm3 was not detected in any of the tissues analyzed
from control mice that had also been exposed to inducer.
These analyses indicate that Cre-mediated disruption of
p63 occurs tissue-specifically and is robust in stratified
epithelia such as the skin.
Histological analysis revealed that the number of hair
follicles was decreased in response to p63 ablation (Fig.
6D). Immunofluorescent analyses demonstrated that
K14 and K1/K10 were expressed in adult skin, demon-
strating that the overall integrity of the skin is main-
tained even when p63 was inactivated within specific
cells (Fig. 6E). To evaluate the extent of p63 ablation in
response to Cre activation, skin from control and p63-
ablated adult mice were costained for expression of p63
and K1/K10 (Fig. 6F). The decrease in p63 nuclear expres-
sion demonstrated that p63 is efficiently ablated in a
subset of keratinocytes in adult epidermis, indicating
that Cre-mediated p63 disruption has occurred.
Given the striking age-associated phenotypes observed
in p63-compromised mice, coupled with the dramatic
increase in cellular senescence observed in response to
p63 deficiency both in vitro and in vivo, we next ana-
lyzed p63-ablated adult skin for senescence. Consistent
with our previous results in embryonic skin, SA--gal
activity was essentially undetectable in control skin, but
was induced in adult skin in response to p63 ablation
(Fig. 6G). To examine whether other proteins implicated
in cellular senescence were simultaneously induced in
response to p63 deficiency, we examined the pattern of
expression of p16INK4a. While p16INK4a expression was
essentially undetectable in control skin, it was dramati-
cally induced in both the interfollicular epidermis and in
the hyperplastic sebaceous glands in p63-ablated skin of
the adult, indicating that as in p63-deficient skin of the
embryo, p63 deficiency in the adult induces cellular se-
nescence (Fig. 6H; Sharpless and DePinho 2004; Campisi
2005). Interestingly, SA--gal/p16INK4a-positive cells
were located at the hair follicle/sebaceous gland junc-
tion, the location of the stem cell niche (Fuchs and
Raghavan 2002). Taken together, these studies indicate
that p63 deficiency induced in squamous epithelia of
adult mice causes enhanced cellular senescence and ac-
celerated aging in vivo.
To explore whether the senescence mediators p53,
p16INK4a, and PML would affect the senescent phenotype
induced by p63 deficiency, we used RNAi technology to
knock down expression of these proteins in primary ke-
ratinocytes while simultaneously inducing p63 ablation.
Real-time PCR and Western analyses demonstrated that
p63flox/flox cultures infected with a control GFP-express-
ing vector retained p63 expression, whereas Cre-infected
cultures had reduced p63 expression at both the tran-
script and protein level (Fig. 7A,B). While an increase in
TAp63 transcripts was noted (Fig. 7A), likely due to the
fact that primers used for this analysis were specific to
exons 2 and 3, which remain intact in the disrupted
p63Brdm3 allele, all detectable p63 isoforms appear to be
depleted at the protein level (Fig. 7B). It is therefore un-
likely that the detectable TA transcript encodes func-
tional TA isoforms since the DBD has been excised and
any truncated protein would be out of frame. In addition,
p63 protein was not detected by Western analyses even
though this p63 antibody was generated against an epi-
tope within exon 4 that should recognize all truncated
p63 proteins. Whereas very few senescent cells were de-
tected in control cultures, Cre-infected cultures became
senescent (Fig. 7C). To determine whether exogenous ex-
pression of DNp63, the predominant isoform expressed
in proliferating keratinocytes, could prevent the senes-
cent phenotype induced by p63 deficiency, parallel cul-
tures were infected with Cre- and DNp63-expressing
constructs simultaneously. Although robust DNp63
expression was attained (Fig. 7C, upper right), these cul-
tures still became senescent, demonstrating that
DNp63 alone is not sufficient for preventing senes-
cence caused by net ablation of p63 (Fig. 7C). To deter-
mine whether p53 is involved in mediating senescence
in this system, cultures were infected with short hairpin
(sh) constructs specific for p53 with and without Cre-
expressing retrovirus. The effectiveness of the sh p53
construct has been demonstrated previously (R. Dickens
and S.W. Lowe, in prep.; J. Silva and G. Hannon, in prep.);
in addition, Western analyses indicate that p53 levels are
reduced in primary keratinocytes infected with the sh
p53 construct (Supplementary Fig. 2A). Strikingly,
knock-down of p53 prevented senescence induced by p63
ablation as seen by normal morphology and the low per-
centage of SA--gal-positive cells (Fig. 7C). In contrast,
Keyes et al.
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parallel cultures infected with retroviral constructs spe-
cific for p16INK4a along with Cre became senescent, in-
dicating that p16INK4a deficiency is not sufficient for pre-
venting the senescent phenotype mediated by p63 loss
(Fig. 7C), even though the two different sh p16INK4a con-
structs used were able to efficiently reduce p16INK4a
levels (Supplementary Fig. 2B). In contrast, similar ex-
periments using shRNA constructs specific for PML
dramatically prevented senescence caused by p63 disrup-
tion (Fig. 7C). These experiments indicate that ablation
of p63 in primary keratinocytes grown in culture medi-
ates a program of cellular senescence that involves p53-
and PML-mediated pathways.
Discussion
This study provides direct in vivo evidence linking the
p53-related protein p63 to both cellular senescence and
aging. Cellular senescence in vitro has been character-
ized functionally by decreased proliferation, morphologi-
cally by microscopic examination of cell shape, and bio-
chemically by the expression of specific markers. p63
deficiency induces senescence in vivo and in vitro, as
measured by each of these criteria; p63 deficiency causes
decreased proliferation, altered morphology, enhanced
SA--gal activity, and increased expression of p16INK4a
and PML (Pearson et al. 2000; Campisi 2001). Although
increased p53 expression is a well-characterized regula-
tor of senescence, we did not detect increased p53 ex-
pression when senescence was induced by p63 deficiency
in vitro or in vivo, and senescence was observed in tis-
sues deficient for both p63 and p53, suggesting that p63
functions either downstream or in a parallel pathway to
p53 in the senescent process. Indeed, DNA-damaging
agents known to induce cellular senescence and to pro-
mote accelerating aging features of the skin, such as UV
irradiation, enhance p53 activity while concomitantly
down-regulating DNp63 (Liefer et al. 2000). Further-
more, the finding that p53 directly binds DNp63 and
targets it for caspase-dependent degradation (Ratovitski
et al. 2001), as well as the similar decrease in life span
and overlapping phenotypes of mice with enhanced p53
(Tyner et al. 2002) and those with compromised p63 (this
Figure 7. Senescence in p63-ablated kera-
tinocytes is prevented by knock-down of p53
and PML, but not by p16INK4a knock-down or
ectopic DNp63 overexpression. (A) Real-
time PCR analysis for the DBD, TA, and N-
terminal truncated (DN) transcripts in re-
sponse to Cre-mediated ablation in primary
keratinocytes. (B) Western blot analysis for
p63 in GFP-infected (V), Cre-infected (C), or
DNp63-infected (DN) keratinocytes, show-
ing that the DNp63 isoform (arrow) and
other putative p63 isoforms (dashed arrows)
are efficiently ablated in Cre-infected cul-
tures. Asterisk denotes nonspecific band. (C,
top right) Real-time PCR analysis for tran-
scripts encoding different p63 isoform sub-
types in keratinocytes infected with GFP,
DNp63, or Cre + DNp63. (Left) Phenotypic
and fluorescent analyses of primary keratino-
cyte cultures infected with GFP- or Cre-ex-
pressing vectors, or with Cre in combination
with DNp63, or with Cre in combination
with short hairpins specific for p53, p16INK4a,
or PML. The proliferation defect was pre-
vented in cultures treated with sh p53 and sh
PML, but not sh p16 or DNp63. (Bottom
right) Cultures were assayed for SA--gal ac-
tivity following infection, and the percentage
of positive cells was quantitated. Bars, 100
µm.
Compromised p63 in senescence and aging
GENES & DEVELOPMENT 1995
 Cold Spring Harbor Laboratory Press on January 12, 2012 - Published by genesdev.cshlp.orgDownloaded from 
study), supports a model in which p63 is directly down-
stream of p53. Although senescence induced by p63 de-
ficiency was p53-independent in vivo, senescence was
prevented when p63 and p53 were simultaneously ab-
lated in primary keratinocytes. The different require-
ment for p53 in senescence in vitro and in vivo could be
due to alterations imposed by cell culture. Alternatively,
distinct cellular responses such as apoptosis or cell ad-
hesion might be specifically affected by depletion of p53
or PML, enhancing overall cell survival. More intrigu-
ingly, the different requirements for p53 in distinct ex-
perimental settings could be the consequence of an al-
teration in the ratio of different p63 isoforms. Indeed,
p53 is dispensable for senescence in mice with germline
p63 deficiency that do not progress past the primitive
ectodermal stage. In contrast, primary keratinocytes
were harvested from mature skin that has already com-
pleted morphogenesis and after a complex pattern of p63
expression has already been established; in this setting,
senescence induced by p63 deficiency is dependent on
p53. Thus, the different requirements for p53 may be due
to interactions between p53-related proteins that differ
in undifferentiated versus mature tissue.
Our data describe a mechanism of senescence induc-
tion that involves increased expression of p16INK4a and
PML, the first data suggesting a link between these pro-
teins and p63. Not only are these key markers of the
senescent pathway, but both p16INK4a and PML are also
potent inducers of senescence, with overexpression of
PML inducing a p53-dependent senescence pathway (Dai
and Enders 2000; Ferbeyre et al. 2000; Pearson et al.
2000). Intriguingly, knock-down of PML, but not
p16INK4a, was sufficient to suppress p63-deficiency-in-
duced senescence in primary keratinocytes. Recent re-
ports, however, also implicate PML as a direct target of
p53 (de Stanchina et al. 2004), and in maintaining the
stability of p53 family members p53 and p73 (Bernardi et
al. 2004; Bernassola et al. 2004). Decreased levels of p63
have been associated with both withdrawal from the cell
cycle and increased expression of cell cycle inhibitors
such as p21 (Westfall et al. 2003; Koster and Roop 2004).
Whether p63 can function as a direct repressor of PML or
p16INK4a, as has been shown for p21, will require further
investigation. However, p63’s ability to modulate genes
involved in renewal, proliferation, and differentiation is
consistent with our findings that compromised p63
causes growth arrest that contributes to the inability to
replenish epithelial tissues, hence leading to accelerated
aging. Furthermore, this check on proliferation may pro-
vide a mechanism for tumor protection, a hypothesis
consistent with the low incidence of tumors in p63 het-
erozygous mutant mice (W.M. Keyes and A.A. Mills, un-
publ.).
p63 deficiency in vivo results in many features of age-
related decline. In elderly patients and in several mouse
models of aging, phenotypic features of accelerated aging
in vivo include: decreased life span, reduced body
weight, lordokyphosis (curvature of the spine), decreased
bone density, decreased organ mass, cellular senescence,
alopecia, increased skin ulcerations and atrophy, de-
creased dermal and adipose thickness, and sebaceous
gland hyperplasia (de Boer et al. 2002; Tyner et al. 2002;
Cao et al. 2003; Hasty et al. 2003; Maier et al. 2004; Sun
et al. 2004; Trifunovic et al. 2004)—many of which we
have described herein in mice with compromised p63.
Although the p63 conditional model disrupts p63 in
specific tissues such as stratified epithelia, age-related
decline was noted globally. It is formally possible that
the observed age-related pathology is caused by Cre-me-
diated disruption of p63 in nonepithelial tissues that is
occurring at levels below that detectable by the PCR
assay used. It is more plausible, however, that the global
aging phenotypes are either direct consequences of p63
deficiency in K5-expressing tissues such as stratified epi-
thelia, or are secondary effects caused by altered tissue
homeostasis mediated by p63 loss in specific tissues in
which p63 is not compromised. While previous studies
have demonstrated that senescence can be communi-
cated from one cell type to another (Krtolica et al. 2001),
future studies will be required to determine whether se-
nescence induced by tissue-specific p63 loss causes ac-
celerated aging in tissues.
Several models of aging directly link C-terminal frag-
ments of p53 to accelerated aging (Tyner et al. 2002;
Maier et al. 2004; Campisi 2005). As the two models
used in the current study involve either germline reduc-
tion/deficiency or somatic ablation of all p63 isoforms
(Mills et al. 1999, 2002), whether distinct p63 proteins
can function in a manner analogous to truncated p53
isoforms or whether specific p63 isoforms regulate cel-
lular senescence and aging remain intriguing possibili-
ties. Indeed, the recent report that p53 also encodes mul-
tiple isoforms adds an additional layer of complexity to
the role of p53 family members in senescence and aging
(Bourdon et al. 2005).
The predominant isoform expressed in mature prolif-
erating epithelia is DNp63, which also correlates with
proliferating cells in both mouse and zebrafish epidermal
development (Yang et al. 1998; Lee and Kimelman 2002).
DNp63 promotes proliferation of basal keratinocytes
by acting as a transcriptional repressor of cell cycle in-
hibitors such as p21 and 14–3–3 (Westfall et al. 2003).
During cell cycle withdrawal and induction of differen-
tiation, this isoform is decreased, freeing up the cell
cycle inhibitors. DNp63 proteins are also increased in
multiple tumor types (Parsa et al. 1999; Hibi et al. 2000),
and overexpression induces -catenin nuclear accumu-
lation and proliferation (Patturajan et al. 2002), consis-
tent with the role of DNp63 in maintaining proliferation
of stratified epithelia. This is in agreement with the find-
ings from both our models that show depletion of the
DNp63 isoform and concomitant loss of proliferation.
Expression of DNp63 was not capable of preventing
p63-deficiency-induced senescence, suggesting that loss
of other p63 isoforms, or combinations thereof, mediates
senescence when depleted. TA- and DN-p63 isoforms are
capable of exerting opposing effects on multiple genes
(Wu et al. 2003), and the fact that DNp63 isoforms can
inhibit transactivation of TAp63 isoforms, the ratio of
different p63 isoforms, as well as their interactions with
Keyes et al.
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other p53 family members, is likely to affect cellular
senescence and hence the aging processes (Maier et al.
2004). Indeed, our finding that p53 deficiency abrogates
senescence induced by p63 loss in vitro indicates that
interactions between p53-related proteins functionally
modulate the senescent process. Further studies using
isoform-specific mouse models and/or RNAi technology
will be useful for determining which p63 isoform(s) nor-
mally regulate the cellular senescence.
Most importantly, our model directly links senescence
with accelerated aging in vivo. The aging process has
been attributed to a decrease in tissue renewal capabil-
ity, possibly by affecting progenitor or stem cell popula-
tions (Park et al. 2004; Sharpless and DePinho 2004;
Campisi 2005). The developing epidermis has been de-
scribed as progenitor-like, and p63 is a key mediator in
skin morphogenesis and maintenance, affecting both the
proliferating keratinocytes and the epidermal stem cells.
Here we describe, in progenitor or stem cell-like popu-
lations, increased expression of p16INK4a and SA--gal
activity, both of which are known to accumulate during
normal aging. Indeed, p16INK4a has recently been sug-
gested to be both a biomarker and an effector of the aging
process (Krishnamurthy et al. 2004). The observation
that mice with compromised p63 levels are not tumor
prone (W.M. Keyes and A.A. Mills, unpubl.) but age pre-
maturely, as in the case of p53+/m mice (Tyner et al.
2002), reinforces the theory that tumor-suppressive
mechanisms such as apoptosis and senescence are ben-
eficial in early life, but may contribute to the aging pro-
cess (Campisi 2001, 2005). Together, our data uncover
two new mechanisms regulated by p63: senescence regu-
lated by p16INK4a and PML, and aging regulated by se-
nescence in proliferating/stem cells, and strengthens
previous reports linking the two processes.
Materials and methods
Mouse strains and genotyping
p63+/− mice harboring the p63Brdm2 allele were used in this
study (Mills et al. 1999). A tumor/aging study was conducted in
which p63+/− (n = 104) and p63+/+ (n = 74) were fed ad libitum
and monitored for malignancies and general health over a 2.2-yr
period. Statistical analysis of survival was performed using the
log-rank test of the Kaplan-Meier format. The p63 conditional
model was generated by crossing p63flox/flox mice (Mills et al.
2002) to p63Brdm2/+; K5CrePR1 mice (Zhou et al. 2002). For em-
bryonic ablation, pregnant females were injected at E8.5–E10.5
with a single intraperitoneal injection of mifepristone (RU486;
500 µg/mL in sesame oil), followed by implantation of a proges-
terone pellet to maintain pregnancy. Newborn or adult (ranging
from 8 to 24 mo) p63flox/flox; K5CrePR1 or p63flox/Brdm2;
K5CrePR1 mice were analyzed following single or sequential
intraperitoneal injections of mifepristone. Skin biopsies were
taken 2–7 d post-injection. Genomic DNA from tail tip biopsies
was digested with BamHI and subjected to Southern analysis to
identify the wild-type p63 locus, as well as the p63Brdm2 and
p63flox alleles, as described previously (Mills et al. 1999, 2002).
PCR was performed with 10 ng of genomic DNA with a Mas-
terCycler gradient thermocycler (Eppendorf) using a 94°C dena-
turation step for 3 min, followed by 40 cycles of 94°C, 55°C, and
72°C for 1 min each. Reaction products were resolved on 2%–
4% agarose gels. The following primers were used to identify
distinct p63 alleles: p63flox FWD, 5-AAGTGGCAGTGAG
CAGAAC-3; p63flox REV, 5-ACAATTCCAGTCAAACATCA
A-3; p63Brdm3 FWD, 5-CAGAGGAGGCAACACAGGATA
GA-3; p63Brdm3 REV, 5-CCGGGGGATCCGAATTCATCGA-
3. The K5CrePR1 transgene and -actin were detected with the
following primers: Cre FWD, 5-CGGTCGATGCAACGAGTG-
3; Cre REV, 5-CCACCGTCAGTACGTGAG-3; -actin FWD,
5-TGGAATCCTGTGGCATCCATGAAAC-3; -actin REV,
5-TAAAACGCAGCTCAGTAACAGTCCG-3.
RT–PCR and real-time PCR analysis
Total RNA was isolated from frozen tissues or cells using Trizol
reagent. A Tissue-Tek homogenizer was used in the case of
tissue. RT–PCR was performed on 0.5 µg of total RNA using a
Superscript first-strand cDNA synthesis kit (Invitrogen). Real-
time PCR was performed according to the manufacturers’ speci-
fications using a Peltier Thermal cycler (MJ Research) and a
SYBR Green PCR kit (Applied Biosystems). Samples were ana-
lyzed in triplicate for at least two separate runs, and were nor-
malized to -actin for each reaction. The following primers
were used: q-actin FWD, 5-GATCTGGCACCACACCTTCT-
3; q-actin REV, 5-GGGGTGTTGAAGGTCTCAAA-3; qp63
DBD FWD, 5-TTATGAGCCACCACAGGTT-3; qp63 DBD
REV, 5-ACGCAGCTGCTGTTACACAT-3; qTAp63 FWD, 5-
CCAGAGGTCTTCCAGCATA-3; qTAp63 REV, 5-TTTCG
GAAGGTTCATCCAC-3; qDNp63 FWD, 5-CTGGAAAAC
AATGCCCAGAC-3; qDNp63 REV, 5-GAGGAGCCGTTCT
GAATCTG-3; qp16 FWD, 5-GTCACACGACTGGGCGATT-
3; qp16 REV, 5-CATGCTGCTCCAGATGGCT-3; qPML
FWD, 5-AGCAGGAGGCTTCTCAGACAG-3; qPML REV, 5-
CTTGATGATCTTCCTGGAAGCA-3.
Culture and infection of primary keratinocytes
Primary keratinocyte cultures were established from 1–2-d-old
wild-type or p63flox/flox mice essentially as previously described
(Lin and Lowe 2001). Retrovirus was produced by transiently
transfecting the Phoenix ecotropic packaging cell line (G. No-
lan, Stanford University, Stanford, CA) with the following con-
structs: pBABE-Cre, pBABE-GFP, MSCV-PIG (Hemann et al.
2003), MSCV DNp63 cDNA-GFP, sh p53 1224 (R. Dickens and
S.W. Lowe, in prep.; J. Silva and G. Hannon, in prep.), sh p16
82.2, sh p16 117-11, and sh PML (de Stanchina et al. 2004).
Cultures were maintained in keratinocyte media prior to virus
collection. Keratinocyte infections were carried out 72–96 h
prior to assaying for endogenous SA--gal activity (Dimri et al.
1995). For experiments involving coculture of Cre with retrovi-
ral short hairpin or DNp63 constructs, cultures were drug-
selected in 1 µg/mL puromycin 48–72 h after infection and
maintained for up to another 6 d before analysis.
Representative counts for SA--gal in vector- and Cre-in-
fected keratinocytes are shown from one of five separate experi-
ments, with the percentage of positive cells counted in tripli-
cate from a total of 200 cells for each count.
Histological, immunofluorescent, and Western analyses
For proliferation analyses, pregnant female mice were injected
with BrdU (Zymed) 1 h prior to tissue harvest. Tissues were
processed for paraffin embedding and hematoxylin and eosin
(H&E) staining. Immunostaining studies were performed using
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standard procedures with the following primary antibodies:
anti-PML (monoclonal 36-1-104; 1:200) (de Stanchina et al.
2004), anti-BrdU (Accurate Chemical and Scientific Corpora-
tion; 1:200), anti-K14-FITC (Covance; 1:1000), anti-Keratin
1,10,11 (RDI; 1:200), anti-p63 (H137; Santa Cruz; 1:200), and
anti-p16INK4a (M156; Santa Cruz; 1:200). Secondary antibodies
were goat-anti-rabbit-HRP (Pierce; 1:2000), goat-anti-mouse Al-
exa fluor 594 (Molecular probes, 1:2000), and goat-anti-rabbit
Alexa fluor 488 (Molecular Probes; 1:2000). Proliferation was
assessed by immunofluorescence, counting the total number of
positive cells in 20 fields of view from two mice of each geno-
type. SA--gal activity was detected in frozen sections as de-
scribed previously (Dimri et al. 1995). Whole-mount embryo
SA--gal was detected similarly following overnight fixation
and incubation with X-gal for 4–6 h. Skin biopsies were har-
vested and subjected to histological staining with H&E.
Immunoblotting was performed on dorsal back skin samples
solubilized in Laemmli buffer. Samples of 10–20 µg of protein
(Bio-Rad protein assay) were analyzed using standard proce-
dures, with antibodies for p63 (monoclonal 4A4; Santa Cruz;
1:800), anti-PML as above (1:1000), and p53 (505; Novacastra;
1:500).
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